Biochemical control and toxicity outcomes of SBRT vs LDR brachytherapy in the treatment of low and intermediate risk prostate cancer.

[1]  A. Kishan,et al.  Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3,502 patients. , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  Jim C Hu,et al.  Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States. , 2020, JAMA network open.

[3]  G. Rodrigues,et al.  Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial , 2019, The Lancet. Oncology.

[4]  L. Beckman,et al.  Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial , 2019, The Lancet.

[5]  C. Elliston,et al.  Stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer: toxicity profile and early oncologic outcomes , 2019, Radiation Oncology.

[6]  S. Abreha.  Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review , 2019, Cost Effectiveness and Resource Allocation.

[7]  M. Zelefsky,et al.  Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer. , 2019, International journal of radiation oncology, biology, physics.

[8]  K. Hoffman,et al.  Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline , 2019, The Journal of urology.

[9]  A. Kishan,et al.  Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer , 2019, JAMA network open.

[10]  Ronald C. Chen,et al.  Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes. , 2018, European urology oncology.

[11]  D. Brachman,et al.  Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints. , 2018, International journal of radiation oncology, biology, physics.

[12]  L. Potters,et al.  Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase 1 Trial for Patients With Low- and Intermediate-Risk Prostate Cancer. , 2018, International journal of radiation oncology, biology, physics.

[13]  Jing Jiang,et al.  Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Roehrborn,et al.  Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer , 2017 .

[15]  M. Zelefsky,et al.  Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials. , 2017, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[16]  J. Lynch,et al.  Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure? , 2017, Front. Oncol..

[17]  M. Shao,et al.  Stereotactic radiotherapy of the prostate: fractionation and utilization in the United States , 2017, Radiation oncology journal.

[18]  Hiram Gay,et al.  Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial. , 2017, International journal of radiation oncology, biology, physics.

[19]  P. Bondiau,et al.  Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy , 2017, Radiation oncology.

[20]  C. Catton,et al.  Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data. , 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

[21]  Ivan Buzurovic,et al.  Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. , 2016, International journal of radiation oncology, biology, physics.

[22]  D. Beyer,et al.  Initial Report of NRG Oncology/RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone for Selected Patients With Intermediate-Risk Prostatic Carcinoma , 2016 .

[23]  A. Kishan,et al.  SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. , 2016, Practical radiation oncology.

[24]  J. Hegde,et al.  A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy , 2016, American Journal of Clinical Oncology.

[25]  É. Vigneault,et al.  Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  R. Hannan,et al.  Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial. , 2016, European journal of cancer.

[27]  William Hsu,et al.  Utilizing time‐driven activity‐based costing to understand the short‐ and long‐term costs of treating localized, low‐risk prostate cancer , 2015, Cancer.

[28]  John T. Wei,et al.  Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  B. Mahal,et al.  Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. , 2015, Brachytherapy.

[30]  P. Wust,et al.  Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer , 2015, Strahlentherapie und Onkologie.

[31]  Josephine Kang,et al.  Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study , 2014, Front. Oncol..

[32]  Yair Lotan,et al.  Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[33]  Jason Wang,et al.  Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[34]  M. Cooperberg,et al.  Primary treatments for clinically localised prostate cancer: a comprehensive lifetime cost‐utility analysis , 2013, BJU international.

[35]  I. Kaplan,et al.  Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinoma , 2012, Cancer.

[36]  James D Brooks,et al.  Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[37]  R. Mohan,et al.  Estimation of α/β for late rectal toxicity based on RTOG 94-06. , 2011, International journal of radiation oncology, biology, physics.

[38]  J. Blasko,et al.  Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. , 2011, International journal of radiation oncology, biology, physics.

[39]  Y. Lotan,et al.  Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Tasca,et al.  Image-Guided Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer: Preliminary Clinical Results , 2010, Technology in cancer research & treatment.

[41]  J. Friedland,et al.  Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer , 2009, Technology in cancer research & treatment.

[42]  J. Fowler,et al.  Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. , 2007, International journal of radiation oncology, biology, physics.

[43]  P. Unger,et al.  Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. , 2005, The Journal of urology.

[44]  M. Kattan,et al.  Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[45]  M. Kattan,et al.  Importance of implant dosimetry for patients undergoing prostate brachytherapy. , 2003, Urology.

[46]  Blasko,et al.  10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. , 2001, International journal of radiation oncology, biology, physics.

[47]  W Cavanagh,et al.  The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[48]  K. Wallner,et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. , 2000, International journal of radiation oncology, biology, physics.

[49]  J. Hendry,et al.  Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. , 2012, International journal of radiation oncology, biology, physics.

[50]  L. Potters,et al.  The role of external radiotherapy in patients treated with permanent prostate brachytherapy , 2002, Prostate Cancer and Prostatic Diseases.

[51]  B. Vikram.  Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma , 1998, Cancer.